SAN JOSE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the quarter ended September 30, 2024 and provided a corporate update.
“We are pleased with the progress we have made this quarter headlined by new preclinical pharmacokinetic data supporting the transenteric delivery of a GLP-1 incretin triagonist. This data, combined with the previously announced pharmacodynamic data from the study, underscores the potential of the RaniPill® to contribute to the GLP-1 receptor agonist space and the broader obesity therapeutics market,” said Talat Imran, Chief Executive Officer of Rani. “Additionally, we raised $20 million in aggregate gross proceeds from financings in July and October, enabling us to extend our cash runway into the third quarter of 2025. Looking ahead, we are excited to start our Phase 1 trial of RT-114 containing a GLP-1/GLP-2 dual agonist for the treatment of obesity next year.”
Third Quarter 2024 and Subsequent Highlights:
Near-Term Milestone Expectations:
Third Quarter 2024 Financial Results:
About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology. For more information, visit ranitherapeutics.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the expected initiation of a Phase 1 trial of RT-114 in 2025, the potential of the RaniPill® platform to contribute to the GLP-1 receptor agonist space and broader obesity therapeutics market, the potential of the RaniPill® platform to enable oral delivery of multiple obesity treatments. the sufficiency of Rani’s cash reserves, the timing and extent of its expenses, and future financial performance. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “intend,” “looking ahead,” “potential,” “expect” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Rani’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Rani’s business in general and the other risks described in Rani’s filings with the Securities and Exchange Commission, including Rani’s annual report on Form 10-K for the year ended December 31, 2023, and subsequent filings and reports by Rani. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Rani undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Investor Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
| RANI THERAPEUTICS HOLDINGS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except par value) | ||||||||
| September 30, | December 31, | |||||||
| 2024 | 2023 | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 4,277 | $ | 5,864 | ||||
| Marketable securities | 26,127 | 42,675 | ||||||
| Prepaid expenses and other current assets | 1,967 | 2,308 | ||||||
| Total current assets | 32,371 | 50,847 | ||||||
| Property and equipment, net | 5,496 | 6,105 | ||||||
| Operating lease right-of-use asset | 5,427 | 718 | ||||||
| Other assets | 246 | 246 | ||||||
| Total assets | $ | 43,540 | $ | 57,916 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,566 | $ | 648 | ||||
| Accrued expenses and other current liabilities | 1,867 | 1,726 | ||||||
| Deferred revenue | 600 | — | ||||||
| Current portion of long-term debt | 14,768 | 4,897 | ||||||
| Current portion of operating lease liability | 1,410 | 718 | ||||||
| Total current liabilities | 20,211 | 7,989 | ||||||
| Long-term debt, less current portion | 13,537 | 24,484 | ||||||
| Operating lease liability, less current portion | 4,017 | — | ||||||
| Total liabilities | 37,765 | 32,473 | ||||||
| Stockholders' equity: | ||||||||
| Preferred stock, $0.0001 par value - 20,000 shares authorized; none issued and outstanding as of September 30, 2024 and December 31, 2023 | — | — | ||||||
| Class A common stock, $0.0001 par value - 800,000 shares authorized; 29,807 and 26,036 issued and outstanding as of September 30, 2024 and December 31, 2023, respectively | 3 | 3 | ||||||
| Class B common stock, $0.0001 par value - 40,000 shares authorized; 24,116 issued and outstanding as of September 30, 2024 and December 31, 2023 | 2 | 2 | ||||||
| Class C common stock, $0.0001 par value - 20,000 shares authorized; none issued and outstanding as of September 30, 2024 and December 31, 2023 | — | — | ||||||
| Additional paid-in capital | 97,067 | 85,762 | ||||||
| Accumulated other comprehensive gain (loss) | 8 | (12 | ) | |||||
| Accumulated deficit | (93,960 | ) | (72,889 | ) | ||||
| Total stockholders' equity attributable to Rani Therapeutics Holdings, Inc. | 3,120 | 12,866 | ||||||
| Non-controlling interest | 2,655 | 12,577 | ||||||
| Total stockholders' equity | 5,775 | 25,443 | ||||||
| Total liabilities and stockholders' equity | $ | 43,540 | $ | 57,916 | ||||
| RANI THERAPEUTICS HOLDINGS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share amounts) (Unaudited) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Operating expenses | ||||||||||||||||
| Research and development | $ | 6,172 | $ | 11,220 | $ | 19,872 | $ | 32,018 | ||||||||
| General and administrative | 5,627 | 6,635 | 18,484 | 20,647 | ||||||||||||
| Total operating expenses | $ | 11,799 | $ | 17,855 | $ | 38,356 | $ | 52,665 | ||||||||
| Loss from operations | (11,799 | ) | (17,855 | ) | (38,356 | ) | (52,665 | ) | ||||||||
| Other income (expense), net | ||||||||||||||||
| Interest income and other, net | 414 | 839 | 1,403 | 2,626 | ||||||||||||
| Interest expense and other, net | (1,337 | ) | (1,316 | ) | (3,909 | ) | (3,789 | ) | ||||||||
| Net loss | $ | (12,722 | ) | $ | (18,332 | ) | $ | (40,862 | ) | $ | (53,828 | ) | ||||
| Net loss attributable to non-controlling interest | (5,939 | ) | (9,135 | ) | (19,791 | ) | (26,956 | ) | ||||||||
| Net loss attributable to Rani Therapeutics Holdings, Inc. | $ | (6,783 | ) | $ | (9,197 | ) | $ | (21,071 | ) | $ | (26,872 | ) | ||||
| Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc., basic and diluted | $ | (0.24 | ) | $ | (0.36 | ) | $ | (0.78 | ) | $ | (1.06 | ) | ||||
| Weighted-average Class A common shares outstanding—basic and diluted | 28,836 | 25,552 | 27,071 | 25,380 | ||||||||||||
| Last Trade: | US$2.10 |
| Daily Change: | 0.06 2.94 |
| Daily Volume: | 48,713 |
| Market Cap: | US$61.510M |
October 17, 2024 August 06, 2024 June 24, 2024 May 06, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
